title: Does bone marrow affect the radiological outcome when added to biphasic ceramic graft in treatment of benign bone lesions?
abstract: OBJECTIVE
  The aim of this study is to describe the role of bone marrow aspirate in treatment of the benign bone lesions by comparing two groups of patients (16 patients in each group) with benign bone lesions treated with surgical curettage and filling the defect with either composite ceramic graft hydrated with bone marrow aspirate "group 1" or composite ceramic graft alone without a bone marrow aspirate "group 2".
  
  
  METHODS
  The mean age was 19.7 years (group 1) and 18.5 years (group 2). The mean size of the cavitary bone lesions was 29.2 cm(2) (group 1) and 25.9 cm(2) (group 2). The mean follow-up period was 47 months.
  
  
  RESULTS
  The percentage of ceraform resorption had increased from 31.3% at 6 months to 75.4% at 36 months for group 1 patients and from 20.9% at 6 months to 60.3% at 36 months for group 2 patients. The percentage of bone trabeculation through the cavitary defects had increased from 30.3% at 6 months to 85.5% at 36 months for group 1 patients and from 18.9% at 6 months to 72.0% at 36 months for group 2 patients. The mean of the percentage of ceraform persistence at 36 months after its implantation was 24.6% for group 1 patients and 39.7% for group 2 patients.
  
  
  CONCLUSIONS
  Adding bone marrow aspirate to ceraform biphasic ceramic had hastened the rate of its resorption and had decreased the rate of its persistence.
authors: Orthopaedic Department, Mansoura Faculty of Medicine, Mansoura University Hospital, Mansoura 35516, Egypt.
authors: Gamal
authors: G
authors: El-Adl
authors: Ayman M
authors: AM
authors: Ali
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001847:Bone Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D001853:Bone Marrow / Q000502:physiology* / Q000601:surgery*; D016026:Bone Marrow Transplantation / Q000379:methods*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002516:Ceramics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003475:Curettage; D005260:Female; D006801:Humans; D006882:Hydroxyapatites / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011859:Radiography; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018786:Bone Substitutes; C509904:Ceraform; D006882:Hydroxyapatites